A Kaplan–Meier analysis showed that the expression of HOXB5 was significantly associated with poor progression-free survival in patients with metastatic PCa treated with ADT (HR 2.221, p = 0.021) (Figure 2C). Here, HOXB5 is linked to posterior cortical atrophy.